Skip to main content
SpringerLink
Log in

Cost-Effectiveness Issues

  • Chapter
Cardiovascular Medicine

  • 193 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Center for Health Statistics. http://www.cdc.gov/nchs/hus.htm. Accessed March 19, 2005.

    Google Scholar 

  2. American Heart Association. Heart Disease and Stroke Statistics—2005 Update. Dallas: American Heart Association, 2005.

    Google Scholar 

  3. Alchian A. The meaning of utility measurement. Am Econ Review 1953;43:26–50.

    Google Scholar 

  4. Spertus JA, Nease RF Jr. Utility assessment. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press, 2003:101–110.

    Google Scholar 

  5. Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989;28:299–308.

    PubMed  CAS  Google Scholar 

  6. Nease RF Jr. Introduction to cost-effectiveness analysis. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press, 2003:111–121.

    Google Scholar 

  7. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999;130:719–728.

    PubMed  CAS  Google Scholar 

  8. Kim C, Kwok YS, Saha S, Redberg RF. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. Am Heart J 1999;137:1019–1027.

    PubMed  CAS  Google Scholar 

  9. Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain. Ann Intern Med 1999;130:709–718.

    PubMed  CAS  Google Scholar 

  10. Tosteson AN, Goldman L, Udvarhelyi IS, Lee TH. Cost-effectiveness of a coronary care unit versus an intermediate care unit for emergency department patients with chest pain. Circulation 1996;94:143–150.

    PubMed  CAS  Google Scholar 

  11. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7–13.

    PubMed  CAS  Google Scholar 

  12. Laffel GL, Fineberg HV, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987;10(5 suppl B):79B–90B.

    PubMed  CAS  Google Scholar 

  13. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991;12:694–699.

    PubMed  CAS  Google Scholar 

  14. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14:108–117.

    PubMed  CAS  Google Scholar 

  15. Herve C, Castiel D, Gaillard M, Boisvert R, Leroux V. Costbenefit analysis of thrombolytic therapy. Eur Heart J 1990;11:1006–1010.

    PubMed  CAS  Google Scholar 

  16. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418–1424.

    PubMed  CAS  Google Scholar 

  17. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995;10:321–330.

    PubMed  CAS  Google Scholar 

  18. Lange RA, Hillis LD. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis—the preferred treatment. N Engl J Med 1996;335:1311–1312;discussion 1316–1317.

    PubMed  CAS  Google Scholar 

  19. Grines CL. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty—the strategy of choice. N Engl J Med 1996;335:1313–1316;discussion 1316–1317.

    PubMed  CAS  Google Scholar 

  20. Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999;282:341–348.

    PubMed  CAS  Google Scholar 

  21. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673–679.

    PubMed  CAS  Google Scholar 

  22. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993;328:685–691.

    PubMed  CAS  Google Scholar 

  23. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–684.

    PubMed  CAS  Google Scholar 

  24. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997;336:1621–1628.

    Google Scholar 

  25. Reeder GS, Bailey KR, Gersh BJ, Holmes DR, Jr., Christianson J, Gibbons RJ. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups. Mayo Clin Proc 1994;69:5–12.

    PubMed  CAS  Google Scholar 

  26. Stone GW, Grines CL, Rothbaum D, et al. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. J Am Coll Cardiol 1997;29:901–907.

    PubMed  CAS  Google Scholar 

  27. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949–1956.

    PubMed  CAS  Google Scholar 

  28. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039–3045.

    PubMed  CAS  Google Scholar 

  29. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol 1998;31:967–972.

    PubMed  CAS  Google Scholar 

  30. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349–360.

    Google Scholar 

  31. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847–860.

    PubMed  CAS  Google Scholar 

  32. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811–815.

    PubMed  CAS  Google Scholar 

  33. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

    PubMed  CAS  Google Scholar 

  34. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838–845.

    PubMed  CAS  Google Scholar 

  35. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447–452.

    PubMed  CAS  Google Scholar 

  36. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events (unstable angina or non-Q-wave myocardial infarction). Circulation 1998;97:1702–1707.

    PubMed  CAS  Google Scholar 

  37. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.

    PubMed  CAS  Google Scholar 

  38. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881–886.

    PubMed  CAS  Google Scholar 

  39. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996;94:629–635.

    PubMed  CAS  Google Scholar 

  40. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445–1453.

    Google Scholar 

  41. Weintraub WS, Culler S, Boccuzzi SJ, et al. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999;34:1061–1066.

    PubMed  CAS  Google Scholar 

  42. Weintraub WS, Thompson TD, Culler S, et al. Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. Circulation 2000;102:392–398.

    PubMed  CAS  Google Scholar 

  43. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366–371.

    PubMed  CAS  Google Scholar 

  44. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89:1545–1556.

    Google Scholar 

  45. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785–1792.

    PubMed  CAS  Google Scholar 

  46. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708–715.

    Google Scholar 

  47. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879–1887.

    PubMed  CAS  Google Scholar 

  48. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851–1858.

    PubMed  Google Scholar 

  49. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.

    PubMed  CAS  Google Scholar 

  50. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152–157.

    PubMed  CAS  Google Scholar 

  51. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411–1420.

    PubMed  CAS  Google Scholar 

  52. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914–919.

    PubMed  CAS  Google Scholar 

  53. McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997;18:1411–1415.

    PubMed  CAS  Google Scholar 

  54. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997;17:222–231.

    PubMed  CAS  Google Scholar 

  55. Weintraub WS, Craver JM, Jones EL, et al. Improving cost and outcome of coronary surgery. Circulation 1998;98(19 suppl):II23–28.

    PubMed  CAS  Google Scholar 

  56. Mauldin PD, Weintraub WS, Becker ER. Predicting hospital costs for first-time coronary artery bypass grafting from preoperative and postoperative variables. Am J Cardiol 1994;74:772–775.

    PubMed  CAS  Google Scholar 

  57. Ellis SG, Miller DP, Brown KJ, et al. In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications. Circulation 1995;92:741–747.

    PubMed  CAS  Google Scholar 

  58. Weintraub WS, Mahoney EM, Ghazzal ZM, et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol 2001;88:497–503.

    PubMed  CAS  Google Scholar 

  59. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117–1124.

    PubMed  CAS  Google Scholar 

  60. Topol EJ, Ellis SG, Cosgrove DM, et al. Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 1993;87:1489–1497.

    PubMed  CAS  Google Scholar 

  61. Cowper PA, DeLong ER, Peterson ED, et al. Geographic variation in resource use for coronary artery bypass surgery. IHD Port Investigators. Med Care 1997;35:320–333.

    PubMed  CAS  Google Scholar 

  62. Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA 2004;291:1841–1849.

    PubMed  CAS  Google Scholar 

  63. Peterson ED, Cowper PA, DeLong ER, Zidar JP, Stack RS, Mark DB. Acute and long-term cost implications of coronary stenting. J Am Coll Cardiol 1999;33:1610–1618.

    PubMed  CAS  Google Scholar 

  64. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation 1995;92:2480–2487.

    PubMed  CAS  Google Scholar 

  65. Weintraub WS. Evaluating the cost of therapy for restenosis: considerations for brachytherapy. Int J Radiat Oncol Biol Phys 1996;36:949–958.

    PubMed  CAS  Google Scholar 

  66. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–1780.

    PubMed  CAS  Google Scholar 

  67. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–1323.

    PubMed  CAS  Google Scholar 

  68. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942–1947.

    PubMed  CAS  Google Scholar 

  69. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508–514.

    PubMed  Google Scholar 

  70. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982;66(5 pt 2):III56–66.

    PubMed  CAS  Google Scholar 

  71. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113:852–871.

    PubMed  CAS  Google Scholar 

  72. King SB 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044–1050.

    PubMed  Google Scholar 

  73. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:217–225.

    Google Scholar 

  74. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994;331:1037–1043.

    PubMed  CAS  Google Scholar 

  75. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 1995;346:1179–1184.

    Google Scholar 

  76. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 1993;22:1060–1067.

    PubMed  CAS  Google Scholar 

  77. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993;341:573–580.

    Google Scholar 

  78. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633–640.

    PubMed  CAS  Google Scholar 

  79. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB 3rd. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995;92:2831–2840.

    PubMed  CAS  Google Scholar 

  80. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997;336:92–99.

    PubMed  CAS  Google Scholar 

  81. Sculpher MJ, Seed P, Henderson RA, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 1994;344:927–930.

    PubMed  CAS  Google Scholar 

  82. Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). J Am Coll Cardiol 1996;27:1178–1184.

    PubMed  CAS  Google Scholar 

  83. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809–1840.

    PubMed  Google Scholar 

  84. Weintraub WS, Mahoney EM, Zhang Z, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 2004;90:782–788.

    PubMed  CAS  Google Scholar 

  85. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10–16.

    PubMed  CAS  Google Scholar 

  86. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70–76.

    PubMed  CAS  Google Scholar 

  87. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461–468.

    Google Scholar 

  88. Kinlay S, Leitch JW, Neil A, Chapman BL, Hardy DB, Fletcher PJ. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann Intern Med 1996;124(1 pt 1):16–20.

    PubMed  CAS  Google Scholar 

  89. Kupersmith J, Hogan A, Guerrero P, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J 1995;130(3 pt 1):507–515.

    PubMed  CAS  Google Scholar 

  90. Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558–566.

    PubMed  CAS  Google Scholar 

  91. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997;126:1–12.

    PubMed  CAS  Google Scholar 

  92. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992;19:1323–1334.

    PubMed  CAS  Google Scholar 

  93. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990;81:91–100.

    PubMed  CAS  Google Scholar 

  94. Wever EF, Hauer RN, Schrijvers G, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation 1996;93:489–496.

    PubMed  CAS  Google Scholar 

  95. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998;97:2129–2135.

    PubMed  CAS  Google Scholar 

  96. Mitchell J, Burge R, Lee A, et al. Per case prospective payment for episodes of hospital care. Publication PB95226023. Springfield, VA: U.S. Department of Commerce National Technical Information Service, 1995.

    Google Scholar 

  97. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.

    PubMed  Google Scholar 

  98. Coats AJ. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials? Int J Cardiol 2002;82:1–5.

    PubMed  Google Scholar 

  99. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005;142:593–600.

    PubMed  Google Scholar 

  100. Kalbfleisch SJ, Calkins H, Langberg JJ, et al. Comparison of the cost of radio-frequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1992;19:1583–1587.

    PubMed  CAS  Google Scholar 

  101. Kertes PJ, Kalman JM, Tonkin AM. Cost effectiveness of radio-frequency catheter ablation in the treatment of symptomatic supraventricular tachyarrhythmias. Aust N Z J Med 1993;23:433–436.

    PubMed  CAS  Google Scholar 

  102. Weerasooriya HR, Murdock CJ, Harris AH, Davis MJ. The cost-effectiveness of treatment of supraventricular arrhythmias related to an accessory atrioventricular pathway: comparison of catheter ablation, surgical division and medical treatment. Aust N Z J Med 1994;24:161–167.

    PubMed  CAS  Google Scholar 

  103. Hogenhuis W, Stevens SK, Wang P, Wong JB, Manolis AS, Estes NA 3rd, Pauker SG. Cost-effectiveness of radio-frequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation 1993;88(5 pt 2):II437–446.

    PubMed  CAS  Google Scholar 

  104. Stamato NJ, O’Toole MF, Enger EL. Permanent pacemaker implantation in the cardiac catheterization laboratory versus the operating room: an analysis of hospital charges and complications. Pacing Clin Electrophysiol 1992;15:2236–2239.

    PubMed  CAS  Google Scholar 

  105. Sutton R, Bourgeois I. Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis of the literature. Eur Heart J 1996;17:574–582.

    PubMed  CAS  Google Scholar 

  106. Rinfret S, Cohen DJ, Lamas GA, et al. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. Circulation 2005;111:165–172.

    PubMed  Google Scholar 

  107. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839–1845.

    PubMed  CAS  Google Scholar 

  108. Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238–248.

    PubMed  CAS  Google Scholar 

  109. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993;148:927–929.

    CAS  Google Scholar 

  110. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992;305:1457–1460.

    PubMed  CAS  Google Scholar 

  111. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998;29:1827–1832.

    PubMed  CAS  Google Scholar 

  112. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998;158:1669–1677.

    PubMed  CAS  Google Scholar 

  113. Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999;130:625–636.

    PubMed  CAS  Google Scholar 

  114. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.

    PubMed  CAS  Google Scholar 

  115. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997;29:122–130.

    PubMed  CAS  Google Scholar 

  116. Klein AL, Murray RD, Becker ER, et al. Economic analysis of a transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation: the ACUTE economic data at eight weeks. J Am Coll Cardiol 2004;43:1217–1224.

    PubMed  Google Scholar 

  117. Centers for Medicare & Medicaid Services. http://www.cms.gov. Accessed February 27, 2005.

    Google Scholar 

  118. Ward RE, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995;26:93–101.

    PubMed  CAS  Google Scholar 

  119. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955–962.

    PubMed  CAS  Google Scholar 

  120. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1–7.

    PubMed  CAS  Google Scholar 

  121. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525–533.

    Google Scholar 

  122. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, ed. Cardiovascular Medicine. Lippincott Williams & Wilkins: Philadelphia: 1997:1193.

    Google Scholar 

  123. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–1456.

    PubMed  CAS  Google Scholar 

  124. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.

    Google Scholar 

  125. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995;1:371–380.

    PubMed  CAS  Google Scholar 

  126. Boyko WL Jr, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. Am Heart J 1999;137:S115–119.

    PubMed  Google Scholar 

  127. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143–1149.

    PubMed  CAS  Google Scholar 

  128. Kleber FX. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases. Am J Hypertens 1994;7(9 pt 2):112S–116S.

    PubMed  CAS  Google Scholar 

  129. van Hout BA, Wielink G, Bonsel GJ, Rutten FF. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. Pharmacoeconomics 1993;3:387–397.

    PubMed  Google Scholar 

  130. Hart W, Rhodes G, McMurray J. The cost effectiveness of enalapril in the treatment of chronic heart failure. Br J Med Econ 1993;6:91–98.

    Google Scholar 

  131. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.

    PubMed  CAS  Google Scholar 

  132. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.

    PubMed  CAS  Google Scholar 

  133. Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002;16:53–59.

    PubMed  CAS  Google Scholar 

  134. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111:1106–1113.

    PubMed  Google Scholar 

  135. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–1355.

    PubMed  CAS  Google Scholar 

  136. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890–896.

    PubMed  CAS  Google Scholar 

  137. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–1195.

    PubMed  CAS  Google Scholar 

  138. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996;334:1441–1447.

    PubMed  CAS  Google Scholar 

  139. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997;79:58–63.

    PubMed  CAS  Google Scholar 

  140. Kornowski R, Zeeli D, Averbuch M, et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J 1995;129:762–766.

    PubMed  CAS  Google Scholar 

  141. Rich MW. Heart failure disease management: a critical review. J Card Fail 1999;5:64–75.

    PubMed  CAS  Google Scholar 

  142. Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med 1999;14:130–135.

    PubMed  CAS  Google Scholar 

  143. Hershberger RE. Clinical outcomes, quality of life, and cost outcomes after cardiac transplantation. Am J Med Sci 1997;314:129–138.

    PubMed  CAS  Google Scholar 

  144. Evans RW. Cost-effectiveness analysis of transplantation. Surg Clin North Am 1986;66:603–616.

    PubMed  CAS  Google Scholar 

  145. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435–1443.

    PubMed  CAS  Google Scholar 

  146. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853.

    PubMed  Google Scholar 

  147. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025–3033.

    PubMed  CAS  Google Scholar 

  148. Tosteson AN, Weinstein MC, Hunink MG, et al. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 1997;95:24–30.

    PubMed  CAS  Google Scholar 

  149. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145–1151.

    PubMed  CAS  Google Scholar 

  150. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Part 2. Ann Intern Med 1996;124:518–531.

    PubMed  CAS  Google Scholar 

  151. Abbott RD, McGee D, Kannel WB, et al. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: W.B. K, P.A. W, R.J. G, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease (publication no. NIH 87:2284). Bethesda: US Department of Health, Education and Welfare, 1987:section 37.

    Google Scholar 

  152. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–1307.

    PubMed  CAS  Google Scholar 

  153. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577–1582.

    PubMed  CAS  Google Scholar 

  154. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.

    Google Scholar 

  155. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796–1802.

    PubMed  CAS  Google Scholar 

  156. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332–336.

    PubMed  CAS  Google Scholar 

  157. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995 26:1133–1139.

    PubMed  CAS  Google Scholar 

  158. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409–414.

    PubMed  CAS  Google Scholar 

  159. http://www.cancer.org/docroot/PED/content/PED_10_2x_Questions_About_Smoking_Tobacco_and_Health.asp (accessed 11/5/06).

    Google Scholar 

  160. http://www.who.int/tobacco/media/USA.pdf (accessed 11/5/06).

    Google Scholar 

  161. United States Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 years of progress. A report of the Surgeon General (DSS Publication NO. CDC89:8411). Washington, DC: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989.

    Google Scholar 

  162. MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use (2). N Engl J Med 1994;330:975–980.

    PubMed  CAS  Google Scholar 

  163. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997;96:1089–1096.

    PubMed  CAS  Google Scholar 

  164. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 1997;11:538–549.

    PubMed  CAS  Google Scholar 

  165. Meenan RT, Stevens VJ, Hornbrook MC, et al. Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care 1998;36:670–678.

    PubMed  CAS  Google Scholar 

  166. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997;278:1759–1766.

    PubMed  CAS  Google Scholar 

  167. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6:1–245.

    CAS  Google Scholar 

  168. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993;22:1697–1702.

    PubMed  CAS  Google Scholar 

  169. Jones TF, Eaton CB. Cost-benefit analysis of walking to prevent coronary heart disease. Arch Fam Med 1994;3:703–710.

    PubMed  CAS  Google Scholar 

  170. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473–2479.

    PubMed  CAS  Google Scholar 

  171. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1997;20(suppl 1):S5–S13.

    Google Scholar 

  172. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663–1669.

    PubMed  CAS  Google Scholar 

  173. Gilmer TP, O’Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847–1853.

    PubMed  CAS  Google Scholar 

  174. The Diabetes Control and Complications Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–986.

    Google Scholar 

  175. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409–1415.

    Google Scholar 

  176. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.

    Google Scholar 

  177. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–744.

    PubMed  CAS  Google Scholar 

  178. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.

    PubMed  CAS  Google Scholar 

  179. Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996;156:1926–1935.

    PubMed  CAS  Google Scholar 

  180. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med 1990;112:192–202.

    PubMed  CAS  Google Scholar 

  181. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:407–413.

    PubMed  CAS  Google Scholar 

  182. Johannesson M, D’Ahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993;234:317–323.

    PubMed  CAS  Google Scholar 

  183. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998;279:1813–1816.

    PubMed  CAS  Google Scholar 

  184. Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999;12:105–114.

    PubMed  CAS  Google Scholar 

  185. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.

    PubMed  CAS  Google Scholar 

  186. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:960–965.

    PubMed  Google Scholar 

  187. Mahoney EM, Chu H. Cost-effectiveness analysis alongside clinical trials: statistical and methodologic issues. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press, 2003:123–156.

    Google Scholar 

  188. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.

    Google Scholar 

  189. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369–390.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Christian Care Health System, Newark, DE, USA

    William S. Weintraub

Authors
  1. William S. Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas Health Science Center in Houston, Houston

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  2. Texas Heart Institute, Houston, TX, USA

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  3. Department of Cardiology, University of Maastricht, Masstricht, The Netherlands

    Hein J. J. Wellens MD (Emeritus Professor) (Emeritus Professor)

  4. Rasmussen Center for Cardiovascular Disease Prevention Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA

    Jay N. Cohn MD (Professor of Medicine and Director) (Professor of Medicine and Director)

  5. Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    David R. Holmes Jr. MD (Consultant, Professor of Medicine and Scripps Professor) (Consultant, Professor of Medicine and Scripps Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Weintraub, W.S. (2007). Cost-Effectiveness Issues. In: Willerson, J.T., Wellens, H.J.J., Cohn, J.N., Holmes, D.R. (eds) Cardiovascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84628-715-2_136

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-715-2_136

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-188-4

  • Online ISBN: 978-1-84628-715-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation